Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Alzheimer’s Disease | Unmet Need | Agitation in Alzheimer’s Disease | US/EU | 2022

Login to access report north_east
Contact sales account_box

In addition to cognitive symptoms, the pharmaceutical industry is focusing on treating the neuropsychiatric symptoms of Alzheimer’s disease (AD), including agitation. According to Clarivate epidemiology, agitation affects the majority of patients diagnosed with AD and comprises a constellation of disruptive symptoms for patients and their families. With competing brands from Lundbeck / Otsuka, Axsome Therapeutics, Avanir / Otsuka, and Intra-Cellular Therapies (among others) poised to enter the market beginning in 2023 and with blockbuster sales at stake, understanding the drivers of clinical decision-making in agitation and prescriber perceptions of the risk / benefit profiles of today’s off-label generic options will help identify levers for new product positioning and differentiation in this evolving market.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for agitation in AD?
  • What attributes drive decision-making in agitation in AD, which have limited impact, and which are hidden opportunities?
  • How do current off-label treatments perform on these attributes?
  • Based on a conjoint analysis and TPP simulation, what trade-offs across key clinical attributes and price are neurologists willing to make for a hypothetical new drug to treat agitation in AD?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European neurologists fielded in February 2022

Key companies: Otsuka / Lundbeck, Avanir / Otsuka, Axsome Therapeutics, Intra-Cellular Therapies 

Key drugs: Quetiapine, risperidone, olanzapine, aripiprazole, sertraline, lorazepam, gabapentin, Rexulti, AVP-786, AXS-05, ITI-1284 ODT-SL

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
north_east
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
north_east
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…
north_east
Report
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east